Balanced Propofol Sedation Versus Propofol Alone Sedation in Therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP)

Overview

Based on previous results, the investigators considered that sedation quality, complications, and procedure outcomes may not be different, however, propofol alone titration may have a fast recovery time than BPS and cost-effectiveness than balanced propofol sedation (BPS). In present study, the investigators therefore evaluate the time and sedation quality of patient recovery, cost-effectiveness, complication, and procedure outcomes between propofol alone and BPS in therapeutic endoscopic retrograde cholangiopancreatography (ERCP).

Full Title of Study: “Phase 4 Study of Balanced Propofol Sedation Versus Propofol Alone Sedation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2011

Detailed Description

Previous studies have shown that propofol is superior to traditional sedation regimens with benzodiazepines plus opioids in ERCP procedures. Propofol is a potent hypnotic drug with a short duration of action and consequently a more rapid recovery time for the patients compared with the available Benzodiazepines. Several prospective studies have shown that balanced propofol sedation (BPS) can be used safely and effectively for diagnostic endoscopy under the direction of a gastroenterologist. BPS which was originally described by Cohen et al, combines small incremental doses of propofol with single induction doses of benzodiazepines and opioids under the direction of a physician that is not an anesthesiologist. Because BPS usually targets moderate sedation, adequate amnesia and analgesia can be achieved with concomitant administration of benzodiazepines and opioids. It may cause synergism between propofol and midazolam and reduce dose of propofol. However, there was no proven benefit between propofol alone titrated to moderate level of sedation and BPS; propofol titration combination with benzodiazepines and fentanyl.

Interventions

  • Drug: Propofol
    • propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV)
  • Drug: BPS
    • midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)

Arms, Groups and Cohorts

  • Active Comparator: Propofol group
    • the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV).
  • Active Comparator: BPS group
    • the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.

Clinical Trial Outcome Measures

Primary Measures

  • Recovery time and cost-effectiveness
    • Time Frame: SIX MONTH
    • Following therapeutic ERCP,full recovery time scoring by Aldrete scoring system and cost measured.

Secondary Measures

  • Sedation efficacy, procedure-related outcomes, and complications.
    • Time Frame: SIX MONTH
    • Sedation efficacy parameters was defined as follows; Onset of effective sedation, Patient cooperation (endoscopist, observer-nurse), recovery time, and Patient tolerance (rated by the patients 4hr after procedure). Quality of procedure was assessed by procedure outcomes and procedure related complications.

Participating in This Clinical Trial

Inclusion Criteria

  • candidates for therapeutic ERCP Exclusion Criteria:

  • patient age < 18 years – pregnant women – inability to provide informed consent – patients with total gastrectomy – American Society of Anesthesiologist (ASA) Class V patients – patients with known respiratory disease, patients with neurologic impairment – patients with known allergy to the drugs used, history of complications with previous sedation

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Soon Chun Hyang University
  • Provider of Information About this Clinical Study
    • Tae Hoon Lee, Soonchunhyang University College of Medicine, Cheonan Hospital
  • Overall Official(s)
    • Tae Hoon Lee, MD, Study Chair, Soonchunhyang University College of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.